Sign in

CIK 0001754068

  • Non-accelerated filer
  • Smaller reporting company

Kalaris Therapeutics, Inc.

Sign in to watch
Ticker
KLRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
831971007
Phone
+1 650-249-2727
Business address
400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
Former names
Allovir, Inc., ViraCyte, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2023-04-20 Hagen Brett R Chief Accounting Officer Sale 10b5-1 −349 $3.63 $1K 134,557
2023-04-19 Sinha Vikas See Remarks Sale 10b5-1 −1,217 $3.71 $5K 1,186,521
2023-04-19 Hagen Brett R Chief Accounting Officer Sale 10b5-1 −348 $3.71 $1K 134,906
2023-04-19 Brainard Diana Chief Executive Officer Sale 10b5-1 −8,408 $3.71 $31K 921,164
2023-03-01 Adams Derek N. Director Grant or award · Stock Option (Right to Buy) +45,000 45,000
2023-02-21 Brainard Diana Chief Executive Officer Sale −5,122 $6.63 $34K 929,572
2023-02-02 Sinha Vikas See Remarks Grant or award +157,500 1,187,738
2023-02-02 Sinha Vikas See Remarks Grant or award · Stock Option (Right to Buy) +292,500 1,012,362
2023-02-02 Miller Edward General Counsel Grant or award +87,500 235,958
2023-02-02 Miller Edward General Counsel Grant or award · Stock Option (Right to Buy) +162,500 497,844
2023-02-02 Leen Ann M. Chief Scientific Officer Grant or award +43,750 124,006
2023-02-02 Leen Ann M. Chief Scientific Officer Grant or award · Stock Option (Right to Buy) +81,250 473,594
2023-02-02 Hagen Brett R Chief Accounting Officer Grant or award +61,250 135,254
2023-02-02 Hagen Brett R Chief Accounting Officer Grant or award · Stock Option (Right to Buy) +113,750 251,708
2023-02-02 Brainard Diana Chief Executive Officer Grant or award +332,500 934,964
2023-02-02 Brainard Diana Chief Executive Officer Grant or award · Stock Option (Right to Buy) +617,500 1,836,875
2023-01-20 Sinha Vikas See Remarks Sale −1,426 $5.14 $7K 1,030,238
2023-01-20 Miller Edward General Counsel Sale −541 $5.14 $3K 148,458
2023-01-20 Hagen Brett R Chief Accounting Officer Sale −338 $5.14 $2K 74,004
2023-01-19 Sinha Vikas See Remarks Sale −5,111 $5.08 $26K 1,031,664

Page 10 of 13 · 259 trades